Company Announcements

Update on Hexima’s development program

Dear Shareholder, I am writing to you to provide an update on Hexima’s development program. Hexima’s lead product (HXP124) is a topical treatment for nail fungus (onychomycosis). HXP124 is an easy to apply solution that is simply painted onto nails, not requiring any...

read more

Hexima announces appointment of Michael Aldridge

Hexima Limited is pleased to announce the appointment of Mr Michael Aldridge as Chief Business Officer and a member of the Board of Directors, effective 21 May 2019. Mr Aldridge will be based in San Francisco, focussing on business development and establishing...

read more

Mr Scott Robertson appointed to Board of Directors

Hexima Limited has announced the appointment of Mr Scott Robertson to its Board of Directors, effective 21 November 2018. Speaking at Hexima’s recent AGM, Chairman Professor Jonathan West said “I am pleased to announce today that we will be adding Mr Scott Robertson...

read more

Chairman and CEO update

It is our pleasure to report on an exciting year at Hexima, during which we progressed our lead drug candidate, HXP124, into first-in-human clinical trials. This is a pivotal step in the development of HXP124 as a safe and effective treatment for fungal nail...

read more

Archives

Categories